Aquestive Therapeutics, Inc.
Anaphylm
Type I allergic reactions, including anaphylaxis
Date
TBD
Phase 3 readout · Date TBD estimated
What's at stake
Phase 3 trial results for Anaphylm in Type I allergic reactions, including anaphylaxis are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 15h ago
“resubmit the Anaphylm New Drug Application (NDA) in the third quarter of 2026”